Sponsors Share Perspectives on Patient Experience Data at FDA’s Request

The collection, use and submission of patient experience data (PED) still requires significantly more FDA guidance, clarification and support, big-name sponsors told the agency in response to a request for information and comments on the subject.
Source: Drug Industry Daily